Shortening baroreflex delay in hypertrophic cardiomyopathy patients - An unknown effect of β-blockers

British Journal of Clinical Pharmacology

Volumn 75, Issue 6, 2013, Pages 1516-1524

  Katarzynska Szymanska, Agnieszka ^a   Ochotny, Romuald ^a   Oko Sarnowska, Zofia ^a   Wachowiak Baszynska, Hanna ^a   Krauze, Tomasz ^a   Piskorski, Jaroslaw ^a,b   Gwizdala, Adrian ^a   Mitkowski, Przemyslaw ^a   Guzik, Przemyslaw ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF ZIELONA GÓRA   (Poland)

Author keywords

blocker; Baroreflex delay; Baroreflex sensitivity; Heart rate variability; Hypertrophic cardiomyopathy

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; FEMALE; HEART RATE VARIABILITY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; SUPINE POSITION;

ADOLESCENT; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; BAROREFLEX; BISOPROLOL; CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; FEMALE; HEART RATE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84878142329     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12027     Document Type: Article

References (49)

1. Maron BJ, Towbin AJ, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention of American Heart Association: contemporary Definitions and Classifications of the Cardiomyopathies. Circulation 2006; 113: 1807-1816.
2. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965-1991.
3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy; executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: 2761-2796.
4. Elliott PE, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000; 6: 2212-2218.
5. Nunez DJ, Clifford CP, al-Mahdawi S, Dutka D. Hypertensive cardiac hypertrophy-is genetic variance the missing link? Br J Clin Pharmacol 1996; 42: 107-117.
6. Harrison DC, Braunwald E, Glick G, Mason D, Chidsey C, Ross J. Effects of beta-adrenergic blockade on the circulation, with particular reference to observation in patients with hypertrophic subaortic stenosis. Circulation 1964; 29: 84-98.
7. Maron BJ, Bonow RO, Canzon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 1987; 316: 780-789.
8. Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 1987; 316: 844-852.
9. Counihan PJ, Frennaux P, Webb DJ, McKenna WJ. Abnormal vascular responses during supine exercise in hypertrophic cardiomyopathy. Circulation 1991; 84: 686-696.
10. Smith OI, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoreceptor antagonist treatment. J Am Coll Cardiol 1999; 34: 1813-1822.
11. Carl I, Ong H, Donnelly R, Riley M, Nicholls DP. Exercise in hypertrophic cardiomyopathy is associated with sympatho-adrenal imbalance. Int J Cardiol 2007; 116: 124-125.
12. Gilligan DM, Chan WL, Sbarouni E, Nihoyannopoulos P, Oakley CM. Autonomic function in hypertrophic cardiomyopathy. Br Heart J 1993; 69: 525-529.
13. Brush JE Jr, Eisenhofer G, Garty M, Stull R, Maron BJ, Cannon RO 3rd, Panza JA, Epstein SE, Goldstein DS. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 1993; 79: 836-844.
14. Kawai C, Yui Y, Hoshino T, Sasayama S, Matsumori A. Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study. J Am Coll Cardiol 1983; 2: 834-840.
15. Thompson DS, Naqvi N, Juul SM, Swanton RH, Coltart DJ, Jenkins BS, Webb-Peploe MM. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J 1980; 44: 488-498.
16. Spoladore R, Maron MS, D'Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 2012; 33: 1724-1733.
17. Lin JL, Chan HL, Du CC, Lin IN, Lai CW, Lin KT, Wu CP, Tseng YZ, Lien WP. Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. Am Heart J 1999; 137: 658-665.
18. Airaksinen KE, Niemelä MJ, Huikuri HV. Effect of beta-blockade on baroreflex sensitivity and cardiovascular autonomic function tests in patients with coronary artery disease. Eur Heart J 1994; 15: 1482-1485.
19. Niemelä MJ, Airaksinen KE, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994; 23: 1370-1377.
20. Lucini D, Pagani M, Mela GS, Malliani A. Sympathetic restraint of baroreflex control of heart period in normotensive and hypertensive subjects. Clin Sci (Lond) 1994; 86: 547-556.
21. Mortara A, La Rovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000; 36: 1612-1618.
22. Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL, Sahn DJ, Schiller NB, Tajik A, Teichholz LE, Weyman AE. Report of American Society of Echocardiography Committee on Nomenclature and Standards in 2-D Echocardiography. Circulation 1980; 62: 212-217.
23. Devereux RB. Left ventricular mass in children and adolescents. J Am Coll Cardiol 1988; 12: 709-714.
24. Task Force of the European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurements, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065.
25. Lomb NR. Least squares frequency analysis unequally spaced data. Astrophys Space Sci 1975; 39: 447-462.
26. Borst C, Karemaker JM. Time delays in the human baroreceptor reflex. J Auton Nerv Syst 1983; 9: 399-409.
27. Eckberg DL. Temporal response patterns of the human sinus node to brief carotid baroreceptor stimuli. J Physiol 1976; 258: 769-782.
28. Westerhof BE, Gisolf J, Stok WJ, Wesseling KH, Karemaker JM. Time-domain cross -correlation baroreflex sensitivity: performance on the EUROBAVAR data set. J Hypertens 2004; 22: 1371-1380.
29. Westerhof BE, Gisolf J, Karemaker JM, Wesseling KH, Secher NH, van Lieshout JJ. Time course analysis of baroreflex sensitivity during postural stress. Am J Physiol Heart Circ Physiol 2006; 291: 2864-2874.
30. Guzik P, Wykretowicz A, Krauze T, Piskorski J, Adamska A, Milewska A, Wesseling KH, Wysocki H. Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system. Hypertens Res 2008; 31: 443-453.
31. Schäfers M, Dutka D, Rhodes CG, Lammertsma AA, Hermansen F, Schober O, Camici PO. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998; 82: 57-62.
32. Lefroy DC, de Silva R, Choudhury L, Uren NG, Crake T, Rhodes CG, Lammertsma AA, Boyd H, Patsalos PN, Nihoyannopoulos P, Oakley CM, Jones T, Camici PG. Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol 1993; 22: 1653-1660.
33. Limbruno U, Strata G, Mengozzi G, Baglini R, Vincenzo A, Leoncini GP, Mariani M. Spectrum analysis of heart rate variability in obstructive hypertrophic myocardiopathy. Evidence of altered autonomic function. Cardiologia 1992; 37: 847-852.
34. Counihan PJ, Fei L, Bashir Y, Farrell TG, Haywood GA, McKenna WJ. Assessment of heart rate variability in hypertrophic cardiomyopathy. Association with clinical and prognosis features. Circulation 1993; 88: 1682-1690.
35. Döven O, Sayin T, Guldal M Karaoguz R, Oral D. Heart rate variability in hypertrophic obstructive cardiomyopathy: association with functional classification and left ventricular outflow gradients. Int J Cardiol 2001; 77: 281-286.
36. Thomson HL, Morris-Thurgood J, Atherton J, Frenneaux M. Reduced cardiopulmonary baroreflex sensitivity in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 31: 1377-1382.
37. Thaman R, Elliott PM, Shah JS, Williams L, Murphy RT, McKenna MJ, Frenneaux MP. Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 883-892.
38. Bauer A, Barthel P, Schneider R, Ulm K, Müller A, Joeinig A, Stich R, Kiviniemi A, Hnatkova K, Huikuri H, Schömig A, Malik M, Schmidt G. Improved Stratification of Autonomic Regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). Eur Heart J 2009; 30: 576-583.
39. Bauer A, Malik M, Schmidt G, Barthel P, Bonnemeier H, Cygankiewicz I, Guzik P, Lombardi F, Müller A, Oto A, Schneider R, Watanabe M, Wichterle D, Zareba W. Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: international Society for Holter and Noninvasive Electrophysiology Consensus. J Am Coll Cardiol 2008; 52: 1353-1365.
40. Frenneaux MP, Counihan PJ, Caforio AC, Chikamori T, McKenna WJ. Abnormal blood pressure responses during exercise in hypertrophic cardiomyopathy. Circulation 1990; 82: 1995-2002.
41. Keyl C, Schneider A, Dambacher M, Bernardi L. Time delay of vagally mediated cardiac baroreflex response varies with autonomic cardiovascular control. J Appl Physiol 2001; 91: 283-289.
42. Gilligan DM, Nihoyannopoulos P, Chan WL, Oakley CM. Investigation of a hemodynamic basis for syncope in hypertrophic cardiomyopathy. Use of a head-up tilt test. Circulation 1992; 85: 2140-2148.
43. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB, Deharo JC, Gajek J, Gjesdal K, Krahn A, Massin M, Pepi M, Pezawas T, Ruiz Granell R, Sarasin F, Ungar A, van Dijk JG, Walma EP, Wieling W. Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS). Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30: 2631-2671.
44. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989; 79: 483-490.
45. Hohnloser S, Klingenheben T, Zabel M, Li Y. Heart rate variability used as an arrhythmia risk stratifier after myocardial infarction. PACE 1997; 20: 2594-2601.
46. La Rovere MT, Schwarz PJ. Baroreflex sensitivity as a cardiac and arrhythmia mortality risk stratifier. PACE 1997; 20: 2602-2613.
47. Guzik P, Piskorski J, Barthel P, Bauer A, Müller A, Junk N, Ulm K, Malik M, Schmidt G. Heart rate deceleration runs for postinfarction risk prediction. J Electrocardiol 2012; 45: 70-76.
48. Mussalo H, Vanninen E, Ikaheimo R, Latinen T, Laakso M, Lansimies E, Hartikainen J. Baroreflex sensitivity in essential and secondary hypertension. Clin Auton Res 2002; 12: 465-471.
49. Johnson P, Shore A, Potter J, Penerai R, James M. Baroreflex sensitivity measured by spectral and sequence analysis in cerebrovascular disease: methodological consideration. Clin Auton Res 2006; 16: 270-275.